Epanova® (omega-3 carboxylic acids)

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Diabetes Mellitus, Type 2Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)Exocrine Pancreatic Insufficiency

Phase 2

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

CompletedNCT02370537

AstraZenecaDiabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency

Start: 2015-03-31End: 2015-11-30Updated: 2017-01-20

Phase 3

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

CompletedNCT02104817

AstraZenecaEligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

Start: 2014-10-30End: 2020-05-27Updated: 2021-08-17

Related Papers

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.

2023-03-06374 citations

Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk

JAMA Cardiology2021-05-1673 citations

Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36

Journal of the American Heart Association2021-04-1228 citations

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

JAMA2020-11-15900 citations

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology2020-02-0831 citations

Importance of pancreatic exocrine dysfunction in patients with type 2 diabetes: A randomized crossover study

Pancreatology2018-05-1919 citations

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

2018-03-2364 citations

Rationale and design of <scp>REDUCE‐IT</scp>: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Clinical Cardiology2017-03-01178 citations

Triglyceride and cardiovascular risk: A critical appraisal

Indian Journal of Endocrinology and Metabolism2016-01-0145 citations

Abstract 17223: Compositional Lipoprotein Changes With Omega-3 Carboxylic Acids in Patients With Hypertriglyceridemia Paired With Low HDL-C: A Substudy From the ESPRIT Trial

Circulation2015-11-10

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.

2015-09-0240 citations